Clinical Trial Update: Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 open-label pilot study assessing CC1004 in severe plaque psoriasis, focusing on pharmacodynamics, pharmacokinetics, safety, and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CC1004

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 2 | Status: COMPLETED